S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
3 Stocks Set to Lead the Nasdaq Bull Market
Norway hits export record amid soaring gas prices
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Myanmar executions revive pressure for more sanctions
Is Ford About To Crush Workhorse Group? 
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
NYSE:ABBV

AbbVie - ABBV Stock Forecast, Price & News

$142.29
-0.31 (-0.22%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$140.42
$143.28
50-Day Range
$137.62
$154.14
52-Week Range
$105.56
$175.91
Volume
4.51 million shs
Average Volume
5.94 million shs
Market Capitalization
$251.58 billion
P/E Ratio
20.15
Dividend Yield
3.96%
Price Target
$159.63

AbbVie MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
12.2% Upside
$159.63 Price Target
Short Interest
Healthy
0.79% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.37mentions of AbbVie in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$40.50 M Sold Last Quarter
Proj. Earnings Growth
-16.01%
From $14.05 to $11.80 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

126th out of 1,125 stocks

Pharmaceutical Preparations Industry

49th out of 554 stocks

ABBV stock logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Price Performance

ABBV Stock traded down $0.10 during mid-day trading on Monday, reaching $142.50. 11,655 shares of the company's stock were exchanged, compared to its average volume of 7,178,582. The company has a market cap of $251.95 billion, a price-to-earnings ratio of 20.20, a price-to-earnings-growth ratio of 4.00 and a beta of 0.70. The stock's 50 day moving average is $146.89 and its 200 day moving average is $150.56. The company has a debt-to-equity ratio of 4.15, a current ratio of 0.84 and a quick ratio of 0.75. AbbVie has a 12-month low of $105.56 and a 12-month high of $175.91.

AbbVie (NYSE:ABBV - Get Rating) last issued its quarterly earnings results on Friday, July 29th. The company reported $3.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. The company had revenue of $14.58 billion for the quarter, compared to the consensus estimate of $14.64 billion. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. AbbVie's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.11 earnings per share. On average, research analysts expect that AbbVie will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be given a $1.41 dividend. The ex-dividend date is Thursday, July 14th. This represents a $5.64 annualized dividend and a dividend yield of 3.96%. AbbVie's dividend payout ratio (DPR) is presently 79.89%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ABBV shares. Wells Fargo & Company raised their price objective on AbbVie from $165.00 to $200.00 in a research report on Monday, May 2nd. BMO Capital Markets boosted their price target on AbbVie from $161.00 to $174.00 and gave the stock an "outperform" rating in a report on Monday, April 25th. Piper Sandler reduced their price objective on AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Atlantic Securities cut their target price on AbbVie from $178.00 to $162.00 and set a "neutral" rating on the stock in a research report on Monday, August 1st. Finally, SVB Leerink initiated coverage on AbbVie in a report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, AbbVie has a consensus rating of "Moderate Buy" and a consensus target price of $159.63.

Insider Activity

In other news, Vice Chairman Michael Severino sold 79,801 shares of the firm's stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $150.90, for a total value of $12,041,970.90. Following the transaction, the insider now owns 152,103 shares in the company, valued at $22,952,342.70. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.08% of the company's stock.

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

Are Medtronic And Intuitive Surgical Poised For Big Growth? (ABBV)
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently.
Two Appealing Biotech Stocks for Two Distinct investors (ABBV)
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
3 Pharma Stocks' Post-Earnings Price Moves
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
MarketBeat: Week in Review 7/25 – 7/29 (ABBV)
The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week.
Should You Buy AbbVie Ahead Of Earnings?
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
MarketBeat: Week in Review 7/18 – 7/22 (ABBV)
Investors should be careful not to read too much into this week's rally. Next week will bring the Fed's decision on interest rates and key earnings reports from the tech sector. Both could cause significant movement in either direction. While you wait, here are some of the stocks our analysts were looking at this week
The ONLY Way to Play Markets Like These
The best investor in the world knows the only way to prosper (especially in markets like these)... is to invest in VALUE. But this $2 stock could be the last value play in the market today. See Why This $2 Stock Could Be $50 and STILL Be a Bargain. pixel
A Dose of AbbVie Stock Can Help Your Bear Market Portfolio
AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that’s exactly why it makes sense to add or hold in your bear market portfolio.
AbbVie: Still A Solid Buy After Modeling Sales To 2030
AbbVie (NYSE:ABBV) Price Target Lowered to $160.00 at Barclays
Want Passive Income? Try These 3 Dividend Stocks
4 "Strong Buy" Stocks for a Fear-Driven Market
What's Happening With AbbVie Stock?
AbbVie (NYSE:ABBV) Given New $160.00 Price Target at Barclays
AbbVie (NYSE:ABBV) PT Lowered to $188.00 at Morgan Stanley
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 8/15 Dividend
7/14/2022
Last Earnings
7/29/2022
Dividend Payable
8/15/2022
Today
8/16/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$159.63
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+12.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

Net Income
$11.54 billion
Pretax Margin
24.54%

Debt

Sales & Book Value

Annual Sales
$56.20 billion
Cash Flow
$17.63 per share
Book Value
$8.73 per share

Miscellaneous

Outstanding Shares
1,768,100,000
Free Float
1,766,683,000
Market Cap
$251.58 billion
Optionable
Optionable
Beta
0.70

Social Links















ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABBV shares.
View ABBV analyst ratings
or view top-rated stocks.

What is AbbVie's stock price forecast for 2022?

16 brokers have issued 1-year price objectives for AbbVie's stock. Their ABBV share price forecasts range from $135.00 to $200.00. On average, they predict the company's stock price to reach $159.63 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts price targets for ABBV
or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2022?

AbbVie's stock was trading at $135.40 at the start of the year. Since then, ABBV shares have increased by 5.1% and is now trading at $142.29.
View the best growth stocks for 2022 here
.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our ABBV earnings forecast
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its earnings results on Friday, July, 29th. The company reported $3.51 earnings per share for the quarter, topping analysts' consensus estimates of $3.42 by $0.09. The business earned $14.58 billion during the quarter, compared to analysts' expectations of $14.64 billion. AbbVie had a trailing twelve-month return on equity of 158.41% and a net margin of 22.03%. AbbVie's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.11 EPS.
Read the conference call transcript
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, June 23rd. Stockholders of record on Friday, July 15th will be given a dividend of $1.41 per share on Monday, August 15th. This represents a $5.64 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend is Thursday, July 14th.
Read our dividend analysis for ABBV
.

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.96%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 79.89%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 47.80% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its third quarter 2022 earnings guidance on Monday, August, 8th. The company provided earnings per share guidance of $3.55-$3.59 for the period, compared to the consensus estimate of $3.67. The company issued revenue guidance of $14.80 billion-$14.80 billion, compared to the consensus revenue estimate of $15.28 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?
What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (4.36%), Northern Trust Corp (1.25%), FMR LLC (0.98%), Franklin Resources Inc. (0.73%), UBS Asset Management Americas Inc. (0.62%) and Swiss National Bank (0.43%). Insiders that own company stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $142.29.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $251.58 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $7.06 on an earnings per share basis.

How many employees does AbbVie have?

The company employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
When was AbbVie founded?

AbbVie was founded in 2013.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.